推荐产品
product name
Merbarone, A cell-permeable anticancer drug that inhibits the catalytic activity of topoisomerase II (topo II) without damaging DNA or stabilizing DNA-topo II cleavable complexes.
品質等級
化驗
≥95% (HPLC)
形狀
solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
faint pink
溶解度
DMSO: 100 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C11H9N3O3S/c15-8(12-6-4-2-1-3-5-6)7-9(16)13-11(18)14-10(7)17/h1-5H,(H,12,15)(H3,13,14,16,17,18)
InChI 密鑰
GFYRZTLCYQQVHZ-UHFFFAOYSA-N
一般說明
A cell-permeable anticancer drug that inhibits the catalytic activity of topoisomerase II (topo II) without damaging DNA or stabilizing DNA-topo II cleavable complexes (IC50 = 20 µM for purified mammalian topo II versus IC50 = ~ 200 µM for topo I). Also induces apoptosis in human leukemic CEM cells through a caspase-3-like protease-dependent mechanism.
A cell-permeable, anticancer drug that inhibits the catalytic activity of DNA topoisomerase II (topo II) without damaging DNA or stabilizing DNA-topo II cleavable complexes (IC50 = 20 µM for purified mammalian topoisomerase II versus IC50 ~200 µM for topoisomerase I). Also induces apoptosis in human leukemic CEM cells through a caspase-3-like protease-dependent mechanism.
生化/生理作用
Cell permeable: yes
Primary Target
Catalytic activity of topoisomerase II
Catalytic activity of topoisomerase II
Product does not compete with ATP.
Reversible: no
Target IC50: 20 µM for purified topoisomerase II (topo II)
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
其他說明
Khelifa, T., and Beck, W.T. 1999. Mol. Pharmacol. 55, 548.
Drake, F.H., et al. 1989. Cancer Res.49, 2578.
Brewer, A.D., et al. 1985. Biochem. Pharmacol.34, 2047.
Drake, F.H., et al. 1989. Cancer Res.49, 2578.
Brewer, A.D., et al. 1985. Biochem. Pharmacol.34, 2047.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
The Journal of cell biology, 219(1) (2019-11-13)
Topoisomerase II (Topo II) is essential for mitosis since it resolves sister chromatid catenations. Topo II dysfunction promotes aneuploidy and drives cancer. To protect from aneuploidy, cells possess mechanisms to delay anaphase onset when Topo II is perturbed, providing additional
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门